Current Status of Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Peripheral T-cell Lymphoma

Huang Wenrong,Liu Daihong
DOI: https://doi.org/10.3760/cma.j.issn.1009-9921.2018.05.014
2018-01-01
Abstract:Peripheral T-cell lymphoma (PTCL) is a kind of heterogeneous neoplasms mostly with strong invasiveness, a tendency of recurrence and drug resistance and poor prognosis. Five year disease-free-survival (DFS) rate of PTCL is less than 30% under the treatment setting of chemotherapy and autologous stem cell transplantation. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a role of a graft-versus-lymphoma effect in the treatment of PTCL, meanwhile, long DFS rate of allo-HSCT for the treatment of relapsed and refractory PTCL reaches 35%-50%. Therefore, allo-HSCT is an effective treatment method for PTCL patients. Key words: Peripheral T-cell lymphoma; Allogeneic hematopoietic stem cell transplantation; Treatment
What problem does this paper attempt to address?